

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Meeting Minutes

Meeting Date: March 15, 2018

Location: Via conference call/WebEx

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:04 PM EST		
A. Minutes from Previous Meeting	G. Shutzberg	Review of Minutes from December 21, 2017	Minutes reviewed, approved	Yes
B. Formulary Review - New Drugs	G. Shutzberg/J. Smith	Baxdela (delafloxacin) tablets		
		Recommendation: • Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	8:0
	K. Slanina/J. Smith	Calquence (acalabrutinib) capsules		
		Recommendation: • Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	8:0
	G. Shutzberg/J. Smith	Solosec (secnidazole) oral granules		
		Recommendation: • Non-preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	8:0
	K. Slanina/J. Smith	Hemlibra (emicizumab) single dose vials		
		Recommendation: • Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	8:0
B. Formulary Review - Class Reviews	K. Slanina/J. Smith	Metastatic Breast Cancer		
		Confirm class review	Yes/No	Yes
		Recommendation: • Verzenio (abemaciclib) tablets: Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina/J. Smith	Nityr (nitisinone) tablets		
		Confirm class review	Yes/No	Yes
		Recommendation: • Nityr (nitisinone) tablets: Preferred with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Orfadin (nitisinone) capsules/oral suspension: Non-preferred with prior authorization across all lines of business. Current utilizers will not be grandfathered.	Motion made, seconded, and carried to accept recommendation	9:0
	Comments:	• Discussion took place to explain the pathway to approval via the prior authorization review process if the member is unable to take the new drug.		
	G. Shutzberg/J. Smith	SGLT2		
		Confirm class review	Yes/No	Yes
		Recommendation: • Jardiance (empagliflozin) tablets: Non-preferred with prior authorization across all lines of business. Current utilizers will not be grandfathered.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Synjardy, Synjardy XR (empagliflozin/metformin) tablets, extended release tablets: Non-preferred with prior authorization across all lines of business. Current utilizers will not be grandfathered.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Invokana (canagliflozin) tablets: Non-preferred with prior authorization across all lines of business. Current utilizers will not be grandfathered.	Motion made, seconded, and carried to accept recommendation	9:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - Class Reviews	G. Shutzberg/J. Smith	Recommendation: • Invokamet, Invokamet XR (canagliflozin/metformin) tablets, extended release tablets: Non-preferred with prior authorization across all lines of business. Current utilizers will not be grandfathered.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Steglatro (ertugliflozin) tablets: Preferred with step therapy across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Segluromet (ertugliflozin/metformin) tablets: Preferred with step therapy across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Qtern (dapagliflozin/saxagliptin) tablets: Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Steglujan (ertugliflozin/sitagliptin) tablets: Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	Comments:	• Discussion regarding 7/1/18 implementation date. Letters will be sent to both members and providers in advance and will also be placing an authorization in the system to allow members to transition. A new prescription from the provider is needed.		
C. Formulary Review - Class Reviews	G. Shutzberg/J. Smith	Rapid Acting Insulin		
		Confirm class review	Yes/No	Yes
		Recommendation: • Humalog U-100 (insulin lispro) vials: Non-preferred with prior authorization across all lines of business. Current utilizers will not be grandfathered.	Motion made, seconded, and carried to accept recommendation	8:1
		Recommendation: • Novolog U-100 (insulin iaspart) vials: Non-preferred with prior authorization across all lines of business. Current utilizers will not be grandfathered.	Motion made, seconded, and carried to accept recommendation	8:1
	Comments:	• Oluwatoyin Fadeyibi documented on the tally to disagree to the 2 insulin items due to the non-grandfathering.		
		Recommendation: • Admelog U-100 (insulin lispro) vials: Preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Admelog U-100 (insulin lispro) pens: Preferred with step therapy across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review - PDL Modifications	G. Shutzberg	Confirm Review of Grid	Yes/No	Yes
	G. Shutzberg	Long-Acting Antimuscarinic/Long-Acting Beta 2-Agonists		
		Recommendation: • Anoro Ellipta (vilanterol/umeclidinium) inhalation: Move to non-preferred with prior authorization across all Medicaid and CHIP lines of business for 4/1/18.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Stiolto Respimat (olodaterol/tiotropium) inhalation spray: Move to preferred across all Medicaid and CHIP lines of business for 4/1/18.	Motion made, seconded, and carried to accept recommendation	9:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - PDL Modifications	G. Shutzberg	Inhaled Corticosteroids		
		Recommendation: • Asmanex HFA/Twisthaler (mometasone) aerosol/powder: Move to non-preferred with prior authorization across all Medicaid and CHIP lines of business except Pennsylvania, New York and Florida Healthy Kids. No change to the CHIP line of business in these three markets for 4/1/18.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Qvar Redihaler (beclomethasone) aerosol: Move to preferred across all Medicaid and CHIP lines of business except Pennsylvania, New York and Florida Healthy Kids. No change to the CHIP line of business in these three markets for 4/1/18.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Growth Hormone		
		Recommendation: • Nutropin AQ Nuspin (somatropin) injection: Move to non-preferred with prior authorization across all Medicaid and CHIP lines of business except Pennsylvania, New York and Florida Healthy Kids. No change to the CHIP line of business in these three markets for 4/1/18.	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Zomacton (somatropin) injection: Move to preferred across all Medicaid and CHIP lines of business except Pennsylvania, New York and Florida Healthy Kids. No change to the CHIP line of business in these three markets for 4/1/18.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Immunomodulators Strategy- NY EPP Plan Only		
		Recommendation: • Actemra (tocilizumab) injection: Preferred with prior authorization for NY EPP Plan only	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Xeljanz/Xeljanz XR (tofacitinib) tablet: Preferred with prior authorization for NY EPP Plan only	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Tremfya (guselkumab) injection: Preferred with prior authorization for NY EPP Plan only	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Probiotics		
		Recommendation: • Products identified as cost-outliers will be non-preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Spinosad 0.9% suspension (generic Natroba)		
		Recommendation: • Preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review - PDL Modifications	G. Shutzberg	Short-Acting Opioids		
		Recommendation: • Oxycodone 10mg, 20mg tablets: Preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	8:1
		Recommendation: • Oxycodone/acetaminophen 7.5/325mg and 10/325mg tablets: Preferred across all lines of business.	Motion made, seconded, and carried to accept recommendation	8:1
	Comments:	• Discussion to confirm that the oxycodone change will be implemented on 7/1/18.		

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - New Drugs- Medical	K. Slanina	Confirm review of grid	Yes/No	Yes
	K. Slanina	Zilretta (triamcinolone acetonide) extended release injection		
		Recommendation: • Medical benefit across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Durolane (hyaluronic acid) injection		
		Recommendation: • Medical benefit across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Mvasi (bevacizumab-awwb) injection		
		Recommendation: • Medical benefit with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Yescarta (axicabtagene ciloleucel) injection		
		Recommendation: • Medical benefit with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Ogivri (trastuzumab-dkst) injection		
		Recommendation: • Medical benefit with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Vabomere (meropenem and vaborbactam) injection		
		Recommendation: • Medical benefit across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Mepsevii (vestronidase alfa-vjvk) injection		
		Recommendation: • Medical benefit across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Fasenra (benralizumab) single-dose prefilled syringes		
		Recommendation: • Medical benefit with prior authorization across all lines of business	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review - New Formulations	G. Shutzberg	Confirm Review of Grid	Yes/No	Yes
	G. Shutzberg	Gocovri (amantadine) extended-release capsules		
		Recommendation: • Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Juluca (dolutegravir and rilpivirine) tablet		
		Recommendation: • Preferred with diagnosis to drug match across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Lyrica CR (pregabalin) extended release tablets		
		Recommendation: • Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	8:1
	Comments:	• Oluwatoyin Fadeyibi documented on the tally to disagree on the opioids and Lyrica is due to opioid crises as rationale - restriction should be more on opioids and less on non-opioid pain options.		
	G. Shutzberg	Xhance (fluticasone propionate) nasal spray		
		Recommendation: • Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Ximino (minocycline) extended release capsules		
		Recommendation: • Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	CaroSpir (spironolactone) oral suspension		
		Recommendation: • Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Fiasp (insulin aspart) injection		
		Recommendation: • Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0
	G. Shutzberg	Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) inhalation		
		Recommendation: • Non-preferred with prior authorization across all lines of business.	Motion made, seconded, and carried to accept recommendation	9:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - Drugs Evaluated Per Grid	G. Shutzberg	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	9:0
C. Clinical Guidelines	K. Slanina	Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	9:0
	K. Slanina	Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	9:0
D. Quality Monitoring	L. Smith/K. Slanina	Confirm Review of Quality Data	Yes/No	Yes
	L. Smith	DUR Review		
	K. Slanina	Top 25 Drugs by Cost and Volume – 4th Quarter 2017		
	K. Slanina	Top 10 Drugs Requested - Approvals and Denials – 4th Quarter 2017		
	K. Slanina	Grievances and Appeals Data – 4th Quarter 2017		
	K. Slanina	Inter-Rater Reliability (IRR) – 1st Quarter 2018 • Pharmacists		
Adjournment	G. Shutzberg		6:31 PM EST	

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer of C&S